Nan Shan Life Insurance Co. Ltd. Increases Stock Holdings in Pfizer Inc. $PFE

Nan Shan Life Insurance Co. Ltd. boosted its holdings in Pfizer Inc. (NYSE:PFE) by 7.7% during the second quarter, Holdings Channel reports. The institutional investor owned 3,306,108 shares of the biopharmaceutical company’s stock after buying an additional 235,799 shares during the period. Pfizer makes up 2.6% of Nan Shan Life Insurance Co. Ltd.’s portfolio, making the stock its 11th biggest holding. Nan Shan Life Insurance Co. Ltd.’s holdings in Pfizer were worth $79,611,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of PFE. Godfrey Financial Associates Inc. purchased a new position in Pfizer during the fourth quarter worth approximately $26,000. Keb Asset Management LLC purchased a new position in shares of Pfizer in the 2nd quarter worth $26,000. Field & Main Bank acquired a new position in Pfizer in the second quarter valued at $27,000. HFM Investment Advisors LLC grew its position in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the period. Finally, Evolution Wealth Management Inc. increased its stake in Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 566 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Strong quarterly results supported the move higher. Pfizer’s second-quarter earnings and revenue exceeded analyst expectations, while full-year 2026 EPS guidance remains $2.80–$3.00. The results suggest resilience despite comparisons with the prior year’s COVID-related performance. Pfizer Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
• Positive Sentiment: Depo-Provera litigation uncertainty has been reduced. Pfizer reached a confidential settlement covering more than 6,000 federal lawsuits alleging a connection between Depo-Provera and intracranial meningioma. Although the financial terms were not disclosed and Pfizer admitted no liability, the agreement removes a significant legal overhang. Pfizer Reaches Confidential Settlement in Depo-Provera Litigation
• Positive Sentiment: Investors are focusing on oncology growth. Padcev, pipeline programs such as PF-08634404 and potential label expansions are central to Pfizer’s effort to offset declining COVID product sales and build longer-term growth. Pfizer’s Oncology Growth Push
• Positive Sentiment: Higher EPS estimates and dividend appeal may be supporting demand. Erste Group Bank increased its FY2026 EPS estimate, while Pfizer’s relatively high dividend yield may attract income-oriented investors seeking defensive healthcare exposure. Pfizer FY2026 EPS Estimate Increased by Erste Group Bank
• Neutral Sentiment: Analysts remain moderately optimistic, but Pfizer has underperformed the S&P 500 over the past year, underscoring continuing concerns about growth and execution. Is Pfizer Stock Underperforming the S&P 500?
• Negative Sentiment: Unusual options activity included purchases of 147,173 put options, about 24% above average. This may reflect bearish positioning or hedging and signals that some traders remain cautious despite the recent rally.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Bank of America cut their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research note on Monday, July 6th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Wolfe Research reissued an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a research note on Thursday, May 14th. Finally, HSBC lowered shares of Pfizer from a “buy” rating to a “hold” rating and reduced their target price for the company from $32.00 to $28.00 in a report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $28.28.

Pfizer Price Performance

PFE stock opened at $28.57 on Wednesday. The stock’s 50 day moving average is $25.69 and its two-hundred day moving average is $26.31. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $29.09. The company has a market capitalization of $162.84 billion, a PE ratio of 37.59 and a beta of 0.34. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Investors of record on Friday, July 24th were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.0%. The ex-dividend date was Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is 226.32%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.